A Phase 2 open-label study of the CSF1R inhibitor JNJ-40346527 in patients with relapsed/refractory acute myeloid leukemia (AML)
This study is being performed to determine the efficacy of the CSF1R inhibitor, JNJ-40346527, in participants with relapsed/refractory acute myeloid leukemia (AML). The safety and survival associated with JNJ-40346527 to treat participants with relapsed/refractory AML will be assessed.
relapsed/refractory acute myeloid leukemia (AML)
Patients diagnosed with relapsed/refractory acute myeloid leukemia (AML).
18 - 99
Healthy Volunteers Needed
Duration of Participation
At least one month or a minimum of 12 months follow-up from the first dose of study drug JNJ-40346527. If there is clinical benefit with treatment study drug will be provided.
Janssen and the Leukemia and Lymphoma Society (LLS)